<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36969198</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1111005</StartPage><MedlinePgn>1111005</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1111005</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1111005</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs. It is often called "immortal cancer" due to the difficulties in disease treatment. As the cornerstone of immune regulation, the programmed cell death protein 1 (PD-1) has been extensively studied in the context of chronic inflammation due to its ability of regulating immune response and immunosuppression. Recently, more and more studies on rheumatic immune related complications have also focused on PD-1 and proposed that the use of PD-1 agonist could inhibit the activation of lymphocytes and alleviate SLE disease activity. In this review, we summarized the role of PD-1 in SLE, implicating its potential application as a biomarker to predict SLE disease activity; we also proposed that the combination of PD-1 agonist and low-dose IL-2 may have better therapeutic efficacy, shining light on a new direction for developing specific treatment approaches.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wang, Chen, Liu, Zhou, Xu and Wu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="Y">Interleukin-2</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061026" MajorTopicYN="Y">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PD-1 agonist</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">pathogenesis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">targeted therapy</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>3</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36969198</ArticleId><ArticleId IdType="pmc">PMC10030866</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1111005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ. Emerging concepts in PD-1 checkpoint biology. Semin Immunol (2021) 52:101480. doi: 10.1016/j.smim.2021.101480</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101480</ArticleId><ArticleId IdType="pmc">PMC8545711</ArticleId><ArticleId IdType="pubmed">34006473</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M. Inflammatory markers in systemic lupus erythematosus. J Autoimmun (2020) 110:102374. doi: 10.1016/j.jaut.2019.102374</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102374</ArticleId><ArticleId IdType="pubmed">31812331</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet (2019) 393(10188):2344&#x2013;58. doi: 10.1016/S0140-6736(19)30546-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen ME, Rus V, Szeto GL. Leveraging heterogeneity in systemic lupus erythematosus for new therapies. Trends Mol Med (2021) 27(2):152&#x2013;71. doi: 10.1016/j.molmed.2020.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2020.09.009</ArticleId><ArticleId IdType="pmc">PMC8667782</ArticleId><ArticleId IdType="pubmed">33046407</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, et al. . Clinical pharmacology and interplay of immune checkpoint agents: A yin-yang balance. Annu Rev Pharmacol Toxicol (2021) 61:85&#x2013;112. doi: 10.1146/annurev-pharmtox-022820-093805</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-022820-093805</ArticleId><ArticleId IdType="pubmed">32871087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer (2021) 12(9):2735&#x2013;46. doi: 10.7150/jca.57334</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.57334</ArticleId><ArticleId IdType="pmc">PMC8040720</ArticleId><ArticleId IdType="pubmed">33854633</ArticleId></ArticleIdList></Reference><Reference><Citation>Karandikar NJ, Vanderlugt CL, Bluestone JA, Miller SD. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J Neuroimmunol (1998) 89(1-2):10&#x2013;8. doi: 10.1016/S0165-5728(98)00058-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(98)00058-7</ArticleId><ArticleId IdType="pubmed">9726820</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH. CTLA-4 and T cell activation. Curr Opin Immunol (1999) 11(3):294&#x2013;300. doi: 10.1016/S0952-7915(99)80047-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0952-7915(99)80047-8</ArticleId><ArticleId IdType="pubmed">10375557</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Li Y, Zhang L, Wang M, Chen Z, Shi J, et al. . Patients with systemic lupus erythematosus show increased proportions of CD19CD20 b cells and secretion of related autoantibodies. Clin Rheumatol (2021) 40(1):151&#x2013;65. doi: 10.1007/s10067-020-05220-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05220-2</ArticleId><ArticleId IdType="pubmed">32542581</ArticleId></ArticleIdList></Reference><Reference><Citation>Siwiec A, Majdan M. The role of the PD-1 protein in pathogenesis of autoimmune diseases, with particular consideration of rheumatoid arthritis and systemic lupus erythematosus. Postepy Hig Med Dosw (2015) 69:534&#x2013;42. doi: 10.5604/17322693.1150784</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/17322693.1150784</ArticleId><ArticleId IdType="pubmed">25983292</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiura D, Maruhashi T, Okazaki I-M, Shimizu K, Maeda TK, Takemoto T, et al. . Restriction of PD-1 function by -PD-L1/CD80 interactions is required for optimal T cell responses. Science (2019) 364(6440):558&#x2013;66. doi: 10.1126/science.aav7062</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav7062</ArticleId><ArticleId IdType="pubmed">31000591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P, Bhattacharya P, Prabhakar BS. A comprehensive review on the role of co-signaling receptors and treg homeostasis in autoimmunity and tumor immunity. J Autoimmun (2018) 95:77&#x2013;99. doi: 10.1016/j.jaut.2018.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.08.007</ArticleId><ArticleId IdType="pmc">PMC6289740</ArticleId><ArticleId IdType="pubmed">30174217</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Nie L, Xu L, Wu X, Zhang S, Xue J. Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity. Scand J Immunol (2020) 92(1):e12884. doi: 10.1111/sji.12884</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12884</ArticleId><ArticleId IdType="pubmed">32243638</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokunina L, Castillejo-L&#xf3;pez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al. . A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet (2002) 32(4):666&#x2013;9. doi: 10.1038/ng1020</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1020</ArticleId><ArticleId IdType="pubmed">12402038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellbacher E, Sundstr&#xf6;m C, Molin D, Baecklund E, Hollander P. Expression of PD-1, PD-L1 and PD-L2 in lymphomas in patients with pre-existing rheumatic diseases-a possible association with high rheumatoid arthritis disease activity. Cancers (Basel) (2022) 14(6). doi: 10.3390/cancers14061509</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14061509</ArticleId><ArticleId IdType="pmc">PMC8946311</ArticleId><ArticleId IdType="pubmed">35326658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J, Yu Y, Ma J, Ren C, Chen W. PD-1+CXCR5-CD4+T cells are correlated with the severity of systemic lupus erythematosus. Rheumatol (Oxford) (2019) 58(12):2188&#x2013;92. doi: 10.1093/rheumatology/kez228</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez228</ArticleId><ArticleId IdType="pubmed">31180450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirahara S, Katsumata Y, Kawasumi H, Kawaguchi Y, Harigai M. Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity. Lupus (2020) 29(7):686&#x2013;96. doi: 10.1177/0961203320916517</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320916517</ArticleId><ArticleId IdType="pubmed">32264742</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Wang L, Li M, Zhang F, Zeng X. The PD-1/PD-L pathway in rheumatic diseases. J Formos Med Assoc (2021) 120(1 Pt 1):48&#x2013;59. doi: 10.1016/j.jfma.2020.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2020.04.004</ArticleId><ArticleId IdType="pubmed">32334916</ArticleId></ArticleIdList></Reference><Reference><Citation>Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 26:677&#x2013;704. doi: 10.1146/annurev.immunol.26.021607.090331</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.26.021607.090331</ArticleId><ArticleId IdType="pubmed">18173375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity (2018) 48(3):434&#x2013;52. doi: 10.1016/j.immuni.2018.03.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.03.014</ArticleId><ArticleId IdType="pmc">PMC7116507</ArticleId><ArticleId IdType="pubmed">29562194</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med (2003) 197(9):1083&#x2013;91. doi: 10.1084/jem.20021752</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021752</ArticleId><ArticleId IdType="pmc">PMC2193977</ArticleId><ArticleId IdType="pubmed">12719480</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L, et al. . Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine (2011) 56(2):231&#x2013;8. doi: 10.1016/j.cyto.2011.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2011.06.004</ArticleId><ArticleId IdType="pubmed">21733718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira RC, Castro Dopico X, Oliveira JJ, Rainbow DB, Yang JH, Trzupek D, et al. . Chronic immune activation in systemic lupus erythematosus and the autoimmune PTPN22 trp risk allele drive the expansion of FOXP3 regulatory T cells and PD-1 expression. Front Immunol (2019) 10:2606. doi: 10.3389/fimmu.2019.02606</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02606</ArticleId><ArticleId IdType="pmc">PMC6857542</ArticleId><ArticleId IdType="pubmed">31781109</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansari MJI, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. . The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 198(1):63&#x2013;9. doi: 10.1084/jem.20022125</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20022125</ArticleId><ArticleId IdType="pmc">PMC2196083</ArticleId><ArticleId IdType="pubmed">12847137</ArticleId></ArticleIdList></Reference><Reference><Citation>Greisen SR, Kragstrup TW, Thomsen JS, H&#xf8;rslev-Pedersen K, Hetland ML, Stengaard-Pedersen K, et al. . The programmed death-1 pathway counter-regulates inflammation-induced osteoclast activity in clinical and experimental settings. Front Immunol (2022) 13:773946. doi: 10.3389/fimmu.2022.773946</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.773946</ArticleId><ArticleId IdType="pmc">PMC8959817</ArticleId><ArticleId IdType="pubmed">35356000</ArticleId></ArticleIdList></Reference><Reference><Citation>Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 14(12):1212&#x2013;8. doi: 10.1038/ni.2762</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2762</ArticleId><ArticleId IdType="pubmed">24240160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S-C, Lin C-H, Ou T-T, Wu C-C, Tsai W-C, Hu C-J, et al. . Ligands for programmed cell death 1 gene in patients with systemic lupus erythematosus. J Rheumatol (2007) 34(4):721&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17343323</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 11(2):141&#x2013;51. doi: 10.1016/S1074-7613(00)80089-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80089-8</ArticleId><ArticleId IdType="pubmed">10485649</ArticleId></ArticleIdList></Reference><Reference><Citation>Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 236:219&#x2013;42. doi: 10.1111/j.1600-065X.2010.00923.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2010.00923.x</ArticleId><ArticleId IdType="pmc">PMC2919275</ArticleId><ArticleId IdType="pubmed">20636820</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Jiang L, Li S-C, He Q-J, Yang B, Cao J. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin (2021) 42(1):1&#x2013;9. doi: 10.1038/s41401-020-0366-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0366-x</ArticleId><ArticleId IdType="pmc">PMC7921448</ArticleId><ArticleId IdType="pubmed">32152439</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol (2018) 18(3):153&#x2013;67. doi: 10.1038/nri.2017.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.108</ArticleId><ArticleId IdType="pubmed">28990585</ArticleId></ArticleIdList></Reference><Reference><Citation>Helou DG, Shafiei-Jahani P, Lo R, Howard E, Hurrell BP, Galle-Treger L, et al. . PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity. Nat Commun (2020) 11(1):3998. doi: 10.1038/s41467-020-17813-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17813-1</ArticleId><ArticleId IdType="pmc">PMC7417739</ArticleId><ArticleId IdType="pubmed">32778730</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. . Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 192(7):1027&#x2013;34. doi: 10.1084/jem.192.7.1027</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.192.7.1027</ArticleId><ArticleId IdType="pmc">PMC2193311</ArticleId><ArticleId IdType="pubmed">11015443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. . Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 169(10):5538&#x2013;45. doi: 10.4049/jimmunol.169.10.5538</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.169.10.5538</ArticleId><ArticleId IdType="pubmed">12421930</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. . Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol (2003) 33(11):3117&#x2013;26. doi: 10.1002/eji.200324270</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200324270</ArticleId><ArticleId IdType="pubmed">14579280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H, Wu X, Gao W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol (2005) 115(2):184&#x2013;91. doi: 10.1016/j.clim.2005.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2005.01.005</ArticleId><ArticleId IdType="pubmed">15885642</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia S, Edidin M, Almo SC, Nathenson SG. Different cell surface oligomeric states of B7-1 and B7-2: Implications for signaling. Proc Natl Acad Sci USA (2005) 102(43):15569&#x2013;74. doi: 10.1073/pnas.0507257102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0507257102</ArticleId><ArticleId IdType="pmc">PMC1266120</ArticleId><ArticleId IdType="pubmed">16221763</ArticleId></ArticleIdList></Reference><Reference><Citation>Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the b cell activation antigen B7. J Exp Med (1991) 174(3):561&#x2013;9. doi: 10.1084/jem.174.3.561</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.174.3.561</ArticleId><ArticleId IdType="pmc">PMC2118936</ArticleId><ArticleId IdType="pubmed">1714933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou J-N, Wiedeman AE, Stevens AM. TNF-&#x3b1; and TGF-&#x3b2; counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep (2012) 2:295. doi: 10.1038/srep00295</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep00295</ArticleId><ArticleId IdType="pmc">PMC3291882</ArticleId><ArticleId IdType="pubmed">22389764</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozaffarian N, Wiedeman AE, Stevens AM. Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1. Rheumatol (Oxford) (2008) 47(9):1335&#x2013;41. doi: 10.1093/rheumatology/ken256</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ken256</ArticleId><ArticleId IdType="pmc">PMC2722808</ArticleId><ArticleId IdType="pubmed">18650228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-M, Chen M-H, Chou K-Y, Chao Y, Chen M-H, Tsai C-Y. Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response. Lupus Sci Med (2022) 9(1). doi: 10.1136/lupus-2022-000693</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000693</ArticleId><ArticleId IdType="pmc">PMC9226994</ArticleId><ArticleId IdType="pubmed">35738802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiura D, Okazaki I-M, Maeda TK, Maruhashi T, Shimizu K, Arakaki R, et al. . PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity. Nat Immunol (2022) 23(3):399&#x2013;410. doi: 10.1038/s41590-021-01125-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01125-7</ArticleId><ArticleId IdType="pubmed">35145298</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E, Perl A. Pathogenesis and treatment of autoimmune rheumatic diseases. Curr Opin Rheumatol (2019) 31(3):307&#x2013;15. doi: 10.1097/BOR.0000000000000594</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000594</ArticleId><ArticleId IdType="pmc">PMC6447054</ArticleId><ArticleId IdType="pubmed">30920455</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Sun T, Song L, Xue X, Liu S, Kuang H, et al. . Interleukin polymorphisms and predisposition of systemic lupus erythematosus: A meta-analysis. Int Arch Allergy Immunol (2021) 182(10):1008&#x2013;16. doi: 10.1159/000507482</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000507482</ArticleId><ArticleId IdType="pubmed">34375975</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M, Wang J, Gong W, Xu H, Pan X, Chen Y, et al. . NF-&#x3ba;B-driven miR-34a impairs Treg/Th17 balance via targeting Foxp3. J Autoimmun (2019) 102:96&#x2013;113. doi: 10.1016/j.jaut.2019.04.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.04.018</ArticleId><ArticleId IdType="pubmed">31130368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. . Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol (2006) 177(12):8844&#x2013;50. doi: 10.4049/jimmunol.177.12.8844</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.12.8844</ArticleId><ArticleId IdType="pubmed">17142787</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. . Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-Severe systemic lupus erythematosus. Arthritis Rheumatol (2017) 69(2):376&#x2013;86. doi: 10.1002/art.39962</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity (2019) 50(4):907&#x2013;23. doi: 10.1016/j.immuni.2019.03.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.025</ArticleId><ArticleId IdType="pmc">PMC6839410</ArticleId><ArticleId IdType="pubmed">30995506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Schnepf D, Staeheli P. Interferon-&#x3bb; orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol (2019) 19(10):614&#x2013;25. doi: 10.1038/s41577-019-0182-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0182-z</ArticleId><ArticleId IdType="pubmed">31201377</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanski A-L, Wiedemann A, Reiter K, Hiepe F, Lino AC, D&#xf6;rner T. Enhanced programmed death 1 and diminished programmed death ligand 1 up-regulation capacity of post-activated lupus b cells. Arthritis Rheumatol (2019) 71(9):1539&#x2013;44. doi: 10.1002/art.40897</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40897</ArticleId><ArticleId IdType="pubmed">30919595</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Ye J, Teng J, Yin Y, Hu Q, Wu X, et al. . Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients. Arthritis Res Ther (2017) 19(1):52. doi: 10.1186/s13075-017-1258-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1258-4</ArticleId><ArticleId IdType="pmc">PMC5343377</ArticleId><ArticleId IdType="pubmed">28274252</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wang J, Kumar V, Karnell JL, Naiman B, Gross PS, et al. . IL-21 drives expansion and plasma cell differentiation of autoreactive CD11cT-bet b cells in SLE. Nat Commun (2018) 9(1):1758. doi: 10.1038/s41467-018-03750-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03750-7</ArticleId><ArticleId IdType="pmc">PMC5931508</ArticleId><ArticleId IdType="pubmed">29717110</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Peng Q, Yang H, Yin L, Shi J, Zhang Y, et al. . Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis. J Rheumatol (2018) 45(6):835&#x2013;40. doi: 10.3899/jrheum.170544</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.170544</ArticleId><ArticleId IdType="pubmed">29419471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, et al. . Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheumatol (2009) 60(1):207&#x2013;18. doi: 10.1002/art.24227</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24227</ArticleId><ArticleId IdType="pubmed">19116915</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, et al. . Safety of programmed death-1 pathway inhibitors among patients with non-Small-Cell lung cancer and preexisting autoimmune disorders. J Clin Oncol (2018) 36(19):1905&#x2013;12. doi: 10.1200/JCO.2017.77.0305</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2017.77.0305</ArticleId><ArticleId IdType="pmc">PMC6553840</ArticleId><ArticleId IdType="pubmed">29746230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassel JC, Heinzerling L, Aberle J, B&#xe4;hr O, Eigentler TK, Grimm M-O, et al. . Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev (2017) 57:36&#x2013;49. doi: 10.1016/j.ctrv.2017.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2017.05.003</ArticleId><ArticleId IdType="pubmed">28550712</ArticleId></ArticleIdList></Reference><Reference><Citation>Orme JJ, Du Y, Vanarsa K, Mayeux J, Li L, Mutwally A, et al. . Heightened cleavage of axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. Clin Immunol (2016) 169:58&#x2013;68. doi: 10.1016/j.clim.2016.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.05.011</ArticleId><ArticleId IdType="pmc">PMC5193537</ArticleId><ArticleId IdType="pubmed">27237127</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde R, Hezaveh K, Halaby MJ, Kloetgen A, Chakravarthy A, da Silva Medina T, et al. . Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. Nat Immunol (2018) 19(6):571&#x2013;82. doi: 10.1038/s41590-018-0107-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0107-1</ArticleId><ArticleId IdType="pmc">PMC5976527</ArticleId><ArticleId IdType="pubmed">29760532</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong JE, Sun L. Targeting the IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities. Trends Pharmacol Sci (2018) 39(3):307&#x2013;25. doi: 10.1016/j.tips.2017.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2017.11.007</ArticleId><ArticleId IdType="pubmed">29254698</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Q, Huang Z, Ye J, Deng Y, Fang L, Li X, et al. . PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus. Arthritis Res Ther (2016) 18:47. doi: 10.1186/s13075-016-0942-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-0942-0</ArticleId><ArticleId IdType="pmc">PMC4751645</ArticleId><ArticleId IdType="pubmed">26867643</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders H-J, Saxena R, Zhao M-H, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers (2020) 6(1):7. doi: 10.1038/s41572-019-0141-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaly S, Rakaee M, Abdi R, Tsokos GC, Fenton KA. Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis. Autoimmun Rev (2021) 20(12):102980. doi: 10.1016/j.autrev.2021.102980</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102980</ArticleId><ArticleId IdType="pubmed">34718163</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W, Zheng H, Wu S, Zhang Y, Wang W, Zhang Z, et al. . The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis. Am J Nephrol (2017) 46(5):371&#x2013;9. doi: 10.1159/000480641</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000480641</ArticleId><ArticleId IdType="pubmed">29069649</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathy R, Panda AK, Das BK. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE. Lupus (2015) 24(1):82&#x2013;9. doi: 10.1177/0961203314552290</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314552290</ArticleId><ArticleId IdType="pubmed">25253568</ArticleId></ArticleIdList></Reference><Reference><Citation>Uribe AG, Vil&#xe1; LM, McGwin G, Sanchez ML, Reveille JD, Alarc&#xf3;n GS. The systemic lupus activity measure-revised, the Mexican systemic lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol (2004) 31(10):1934&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15468356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus D, Matos A, Henriques C, Zen M, Larosa M, Iaccarino L, et al. . Derivation and validation of the SLE disease activity score (SLE-DAS): A new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis (2019) 78(3):365&#x2013;71. doi: 10.1136/annrheumdis-2018-214502</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214502</ArticleId><ArticleId IdType="pubmed">30626657</ArticleId></ArticleIdList></Reference><Reference><Citation>In&#xea;s L, Duarte C, Silva RS, Teixeira AS, Fonseca FP, da Silva JAP. Identification of clinical predictors of flare in systemic lupus erythematosus patients: A 24-month prospective cohort study. Rheumatol (Oxford) (2014) 53(1):85&#x2013;9. doi: 10.1093/rheumatology/ket322</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket322</ArticleId><ArticleId IdType="pubmed">24067885</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M, Saccon F, Zen M, Bettio S, Iaccarino L, Punzi L, et al. . Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. J Autoimmun (2016) 74:94&#x2013;105. doi: 10.1016/j.jaut.2016.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.06.014</ArticleId><ArticleId IdType="pubmed">27373904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, et al. . Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis (2018) 77(1):104&#x2013;10. doi: 10.1136/annrheumdis-2017-211613</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211613</ArticleId><ArticleId IdType="pubmed">28970217</ArticleId></ArticleIdList></Reference><Reference><Citation>Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. . PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol (2021) 18(6):345&#x2013;62. doi: 10.1038/s41571-021-00473-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-021-00473-5</ArticleId><ArticleId IdType="pubmed">33580222</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran CS, Gupta S, Sanz I, Sharon E. PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun (2019) 97:1&#x2013;9. doi: 10.1016/j.jaut.2018.10.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.10.025</ArticleId><ArticleId IdType="pmc">PMC7449827</ArticleId><ArticleId IdType="pubmed">30396745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bally APR, Lu P, Tang Y, Austin JW, Scharer CD, Ahmed R, et al. . NF-&#x3ba;B regulates PD-1 expression in macrophages. J Immunol (2015) 194(9):4545&#x2013;54. doi: 10.4049/jimmunol.1402550</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1402550</ArticleId><ArticleId IdType="pmc">PMC4402259</ArticleId><ArticleId IdType="pubmed">25810391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Garc&#xed;a M, Porichis F, de Jong OG, Levi K, Diefenbach TJ, Lifson JD, et al. . Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol (2011) 89(4):507&#x2013;15. doi: 10.1189/jlb.0610327</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0610327</ArticleId><ArticleId IdType="pmc">PMC3058820</ArticleId><ArticleId IdType="pubmed">21097698</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. . Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep (2017) 19(6):1189&#x2013;201. doi: 10.1016/j.celrep.2017.04.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.04.031</ArticleId><ArticleId IdType="pmc">PMC6420824</ArticleId><ArticleId IdType="pubmed">28494868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bally APR, Austin JW, Boss JM. Genetic and epigenetic regulation of PD-1 expression. J Immunol (2016) 196(6):2431&#x2013;7. doi: 10.4049/jimmunol.1502643</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1502643</ArticleId><ArticleId IdType="pmc">PMC4780223</ArticleId><ArticleId IdType="pubmed">26945088</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 controls follicular T helper cell positioning and function. Immunity (2018) 49(2):264&#x2013;74. doi: 10.1016/j.immuni.2018.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.06.012</ArticleId><ArticleId IdType="pmc">PMC6104813</ArticleId><ArticleId IdType="pubmed">30076099</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, et al. . Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest (2003) 112(10):1506&#x2013;20. doi: 10.1172/JCI200319301</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200319301</ArticleId><ArticleId IdType="pmc">PMC259134</ArticleId><ArticleId IdType="pubmed">14617752</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J-Y, Ho J-e, Pasoto SG, Bunin V, Kim ST, Carrasco S, et al. . Circulating follicular helper-like T cells in systemic lupus erythematosus: Association with disease activity. Arthritis Rheumatol (2015) 67(4):988&#x2013;99. doi: 10.1002/art.39020</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39020</ArticleId><ArticleId IdType="pmc">PMC4450082</ArticleId><ArticleId IdType="pubmed">25581113</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripoll &#xc8;, Merino A, Herrero-Fresneda I, Aran JM, Goma M, Bola&#xf1;os N, et al. . CD40 gene silencing reduces the progression of experimental lupus nephritis modulating local milieu and systemic mechanisms. PloS One (2013) 8(6):e65068. doi: 10.1371/journal.pone.0065068</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065068</ArticleId><ArticleId IdType="pmc">PMC3683035</ArticleId><ArticleId IdType="pubmed">23799000</ArticleId></ArticleIdList></Reference><Reference><Citation>Curnock AP, Bossi G, Kumaran J, Bawden LJ, Figueiredo R, Tawar R, et al. . Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight (2021) 6(20). doi: 10.1172/jci.insight.152468</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.152468</ArticleId><ArticleId IdType="pmc">PMC8564903</ArticleId><ArticleId IdType="pubmed">34491911</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Lee CK, Lin C-H, Gassen RB, Xu X, Huang Z, et al. . PD-L1:CD80 cis-heterodimer triggers the Co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways. Immunity (2019) 51(6):1059&#x2013;73. doi: 10.1016/j.immuni.2019.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.11.003</ArticleId><ArticleId IdType="pmc">PMC6935268</ArticleId><ArticleId IdType="pubmed">31757674</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 209(6):1201&#x2013;17. doi: 10.1084/jem.20112741</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20112741</ArticleId><ArticleId IdType="pmc">PMC3371732</ArticleId><ArticleId IdType="pubmed">22641383</ArticleId></ArticleIdList></Reference><Reference><Citation>Torkildsen &#xd8;, Myhr KM, B&#xf8; L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol (2016) 23 Suppl 1(Suppl 1):18&#x2013;27. doi: 10.1111/ene.12883</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12883</ArticleId><ArticleId IdType="pmc">PMC4670697</ArticleId><ArticleId IdType="pubmed">26563094</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara C, Sugrue G, Murray B, MacMahon PJ. Current and emerging therapies in multiple sclerosis: Implications for the radiologist, part 2-surveillance for treatment complications and disease progression. AJNR Am J Neuroradiol (2017) 38(9):1672&#x2013;80. doi: 10.3174/ajnr.A5148</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A5148</ArticleId><ArticleId IdType="pmc">PMC7963720</ArticleId><ArticleId IdType="pubmed">28428206</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. . iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol (2017) 18(3):e143&#x2013;e52. doi: 10.1016/S1470-2045(17)30074-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(17)30074-8</ArticleId><ArticleId IdType="pmc">PMC5648544</ArticleId><ArticleId IdType="pubmed">28271869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao H, Nakayamada S, Yamagata K, Ohkubo N, Iwata S, Inoue Y, et al. . Conversion of T follicular helper cells to T follicular regulatory cells by interleukin-2 through transcriptional regulation in systemic lupus erythematosus. Arthritis Rheumatol (2021) 73(1):132&#x2013;42. doi: 10.1002/art.41457</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41457</ArticleId><ArticleId IdType="pubmed">32720470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Nakayamada S, Kubo S, Sakata K, Yamagata K, Miyazaki Y, et al. . Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Ann Rheum Dis (2018) 77(9):1354&#x2013;61. doi: 10.1136/annrheumdis-2017-212652</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212652</ArticleId><ArticleId IdType="pubmed">29853448</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. . Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med (2016) 22(9):991&#x2013;3. doi: 10.1038/nm.4148</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4148</ArticleId><ArticleId IdType="pubmed">27500725</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv C, Zhang H, Li Z, Zhang H, Zhang Y, Li R, et al. . Low-dose IL-2 therapy compensates for metabolic shifts and reverses anxiety-like behavior in PD-1 deficiency-induced autoimmunity. Cell Mol Immunol (2021) 18(5):1336&#x2013;8. doi: 10.1038/s41423-020-00562-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00562-y</ArticleId><ArticleId IdType="pmc">PMC8093245</ArticleId><ArticleId IdType="pubmed">33067573</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Hou B, Fulzele A, Masubuchi T, Zhao Y, Wu Z, et al. . PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J Cell Biol (2020) 219(6). doi: 10.1083/jcb.201905085</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201905085</ArticleId><ArticleId IdType="pmc">PMC7265324</ArticleId><ArticleId IdType="pubmed">32437509</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida T, Shibayama S, et al. . PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol (2009) 182(11):6682&#x2013;9. doi: 10.4049/jimmunol.0900080</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900080</ArticleId><ArticleId IdType="pubmed">19454662</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, et al. . PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood (2017) 129(15):2186&#x2013;97. doi: 10.1182/blood-2016-09-741629</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-09-741629</ArticleId><ArticleId IdType="pmc">PMC5391624</ArticleId><ArticleId IdType="pubmed">28151427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurata I, Mikami N, Ohyama A, Osada A, Kondo Y, Tsuboi H, et al. . Impaired function of PD-1 follicular regulatory T cells in systemic lupus erythematosus. Clin Exp Immunol (2021) 206(1):28&#x2013;35. doi: 10.1111/cei.13643</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13643</ArticleId><ArticleId IdType="pmc">PMC8446397</ArticleId><ArticleId IdType="pubmed">34240405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Nasr M, Tezza S, D'Addio F, Mameli C, Usuelli V, Maestroni A, et al. . PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci Transl Med (2017) 9(416). doi: 10.1126/scitranslmed.aam7543</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aam7543</ArticleId><ArticleId IdType="pmc">PMC6171337</ArticleId><ArticleId IdType="pubmed">29141886</ArticleId></ArticleIdList></Reference><Reference><Citation>Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt FA, Liniany LP, Knight D, et al. . PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells. Immunity (2018) 49(2):247&#x2013;63. doi: 10.1016/j.immuni.2018.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.05.006</ArticleId><ArticleId IdType="pmc">PMC6105434</ArticleId><ArticleId IdType="pubmed">30054205</ArticleId></ArticleIdList></Reference><Reference><Citation>Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 19(7):813&#x2013;24. doi: 10.1093/intimm/dxm057</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxm057</ArticleId><ArticleId IdType="pubmed">17606980</ArticleId></ArticleIdList></Reference><Reference><Citation>Grakoui A, John Wherry E, Hanson HL, Walker C, Ahmed R. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J Hepatol (2006) 45(4):468&#x2013;72. doi: 10.1016/j.jhep.2006.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2006.07.009</ArticleId><ArticleId IdType="pubmed">16901572</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryan CM, Rocklin GJ, Bick MJ, Ford A, Majri-Morrison S, Kroll AV, et al. . Computational design of a synthetic PD-1 agonist. Proc Natl Acad Sci USA (2021) 118(29). doi: 10.1073/pnas.2102164118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2102164118</ArticleId><ArticleId IdType="pmc">PMC8307378</ArticleId><ArticleId IdType="pubmed">34272285</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Chen C, Wu Z, Zhang W, Wang L, Yu J, et al. . Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus. Biomaterials (2022) 285:121517. doi: 10.1016/j.biomaterials.2022.121517</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2022.121517</ArticleId><ArticleId IdType="pubmed">35504179</ArticleId></ArticleIdList></Reference><Reference><Citation>Karamitopoulou E, Andreou A, Pahud de Mortanges A, Tinguely M, Gloor B, Perren A. PD-1/PD-L1-Associated immunoarchitectural patterns stratify pancreatic cancer patients into Prognostic/Predictive subgroups. Cancer Immunol Res (2021) 9(12):1439&#x2013;50. doi: 10.1158/2326-6066.CIR-21-0144</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-21-0144</ArticleId><ArticleId IdType="pubmed">34526323</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley JL. PD-1 signaling in primary T cells. Immunol Rev (2009) 229(1):114&#x2013;25. doi: 10.1111/j.1600-065X.2009.00767.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2009.00767.x</ArticleId><ArticleId IdType="pmc">PMC3424066</ArticleId><ArticleId IdType="pubmed">19426218</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley JL, June CH. The CD28 family: A T-cell rheostat for therapeutic control of T-cell activation. Blood (2005) 105(1):13&#x2013;21. doi: 10.1182/blood-2004-04-1596</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-04-1596</ArticleId><ArticleId IdType="pubmed">15353480</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>